ADNAB Partnership with Mayo Clinic1
A breakthrough proprietary next generation ADC platform
Based on work of Svetomir Markovic and colleagues at the Mayo Clinic2,3
Enables the binding of antibodies to drug payloads for oncology and beyond
Circumvents the need for:
- Use of covalent “linker” technology
- Internalization into the cell
Known, clinically active antibodies are non-covalently bound to drug payloads by construction of a patented admixture of
- One or more therapeutically or immunologically active antibodies
- A “particle” of albumin
- The drug payload
Investigator initiated proof of concept studies are ongoing in B cell lymphoma, melanoma, and gynecological cancers
Intellectual property portfolio comprised of 17 patent families, 32 patents granted to date with life through at least 2035 and another 135 patents pending.
1) In 2020, Sorrento obtained exclusive license to develop and commercialize ADNAB in partnership with Mayo Clinic
2) Nevala W, et al. Antibody-targeted chemotherapy for the treatment of melanoma. Cancer Res. 2016; 76:3954-3964. 2
3) Butterfield JT, et al. Identification of a peptide-peptide binding motif in the coating of nab-paclitaxel nanoparticles with clinical antibodies: bevacizumab, rituximab, and trastuzumab. Sci Rep. 2017; 7:14476.